SEQENSgroup

INVESTING IN CUTTING-EDGE TECHNOLOGIES

This investment of 30 million euros in one of the 3 leading technologies in pharmaceutical synthesis demonstrates the SEQENS group’s ability to design, develop and industrialize the most complex molecules while maintaining a high level of performance in terms of quality, safety and respect for the environment.

This project called UPP30 has been carried out in partnership with the Belgian biotech company Mithra for the production of a fifth-generation contraceptive molecule with a superior safety profile for women and with a very high level of biodegradability giving it a major environmental interest.

It demonstrates the interest for both major pharmaceutical laboratories and biotech companies to rely on local and perennial skills for the development and industrialization of their molecules.

Emmanuel Macron, President of the French Republic and Jean-Philippe Aubert, Head of the HPAPI unit project

DISCOVER OUR NEWS

Learn more